Solaris Pharma Corporation located Bridgewater, New Jersey announces the final approval from U.S Food and Drug Administration for its Abbreviated New Drug Application for Clindamycin Phosphate Gel USP, 1% (Once-A-Day) in 75 mL bottle a generic version of reference listed drug Clindagel® (clindamycin phosphate) topical gel, 1%. For more updates, please visit the products page or email us directly at info@solaris-pharma.com
Aug 13, 2021
Updated: Aug 17, 2021